The Fight for Identity in Pharma Data

by Marina VasquezHead of Semantic Systems, HMND

summary

The hottest work in pharma data right now sits in the semantic layer, where teams are trying to make a sample, an assay, a study, and a material mean the same thing across research, clinical, and manufacturing systems. Recent writing on knowledge graphs, metadata automation, and governed interoperability points in the same direction: shared meaning has to come before shared dashboards, or every downstream decision keeps paying a translation tax.

A lab can have all the storage it wants and still fail the basic question. When one system thinks a sample is a specimen, another thinks it is a container, and a third thinks it is a row in a warehouse export, the company does not have integration. It has disagreement with better cables.

body

The last week’s momentum around semantic infrastructure has been loud for a reason. The people building knowledge graphs and semantic catalogs are finally talking less about pretty diagrams and more about the exact business objects that keep breaking in real pipelines, with explicit semantic models, active metadata, and federated identity all showing up as the repair kit for data that must survive movement across systems.

That shift matters most in pharma, where the same word can mean three different things by lunchtime. A sample in a discovery lab is a physical thing with chain of custody, an assay in the clinical world may be a validated test with method constraints and regulatory meaning, and a material in manufacturing can be a controlled input tied to batch, site, and release state. If those entities are modeled as the same loose noun because someone needed a dashboard by Friday, the machine will keep answering confidently in the wrong language.

I have watched this failure up close in a room full of smart people. The team had a warehouse, a catalog, and a layer called integration, which is usually where the trouble starts. The biologist wanted the provenance of a sample lineage, the clinician wanted the exact test context, and the manufacturing lead wanted to know whether a material lot had the same identity after transfer. They were all asking for a decision the organization could not yet make because no one had agreed on what the thing was before the thing moved.

That is why the current wave of metadata automation is more interesting than the usual platform theater. Automated annotation and semantic cataloging only help when the ontology is honest enough to name the entity that should exist and does not yet exist in the source system. Knowledge graphs do useful work here because they let organizations attach meaning to relationships, not just store records beside each other, and they can do it across silos without pretending the silos vanished.

Clinical and scientific interoperability still gets described as transport, but transport is the easy part. The hard part is semantic agreement, because a compliant query that returns the wrong unit of meaning is still a failure, just a tidier one. Recent work on governed data access and federated architectures makes the same point from another angle, showing that identity, access, and meaning have to move together if researchers and regulated teams are going to reuse data without reinterpreting it by hand.

This is where pharma keeps losing time. Teams argue about dashboards because dashboards are visible, and identity is shy. Identity lives in the model, in stewardship, in the rules for how a sample inherits context, how an assay version is distinguished from a method family, how a study binds protocol to subject, how a material lot survives a site transfer without becoming a new thing by accident. That is governance work, and it has teeth.

The useful decision is made earlier than most org charts admit. A company needs a data model and governance layer that can say, with one shared vocabulary, what exists, who may name it, how it relates to other entities, and which systems are allowed to alter that meaning. Until that layer is real, every new integration is just another place for translation loss to hide.

Marina Vasquez
If this identity mess is sitting inside your lab or quality stack, hello@example.com is where the conversation starts.